Objective:
To review progress toward hepatitis C elimination, gaps in prevention and treatment, strategies for reaching populations facing care barriers, and investigational prevention and treatment approaches.
Approach:
- : Ward reviewed global estimates, national programs, priority populations and barriers involving prevention services, financing and confirmatory testing costs.
- : Terrault discussed U.S. care gaps, Veterans Affairs initiatives, hospital-based treatment and emergency-department screening.
- : Trooskin addressed integrated care for populations facing barriers. Thomas reviewed vaccine research and a potential single-injection treatment.
Key Findings:
- Ward cited approximately 47 million people with hepatitis C worldwide, about 20% fewer than in 2015. Incidence declined about 8% and deaths about 12%, below the respective 2030 reduction goals of 90% and 65%.
- Egypt reduced prevalence from 10% to 0.4%. England reported declines of 61% in general-population prevalence and 18% in mortality during 2015-2024. Spain reported declines of 40% in general-population prevalence, 53% in mortality and 92% in prevalence among incarcerated people during 2015-2023.
- Terrault reported that approximately 68% of U.S. patients had been diagnosed and 43% of diagnosed patients had received treatment, compared with targets of 90% and 80%.
- In OPPORTUNI-C, treatment initiation within six months reached 85.7% with hospital-based assessment and treatment or rapid post-discharge care, versus 46.1% with usual outpatient referral.
- In DETECT Hep C, nontargeted emergency-department screening produced a 34% higher diagnosis rate than targeted screening, but substantial losses occurred before linkage to care.
- In HERO, per-protocol sustained virologic response rates exceeded 90%; intention-to-treat rates were lower. A separate analysis found response rates above 90% with medication adherence as low as 50%. Trooskin encouraged completing all prescribed medication.
- Montreal modeling projected that prison-based testing and treatment could reduce incidence by 48% and prevent 22% of new chronic infections; adding risk reduction increased the projected proportion prevented to 35%.
- A vaccine trial generated immune responses but did not reduce progression to chronic infection. Injectable glecaprevir/pibrentasvir showed prolonged drug exposure in rats, with human testing planned for 2027.
Interpretation:
Ward characterized elimination as increasingly a political commitment challenge. Speakers emphasized financing, prevention, integration into existing services and focused efforts in populations facing care barriers.
Limitations:
- The article summarizes selected findings without complete study methods or confidence intervals.
- Global figures include estimates, and the Montreal findings are projections.
- HERO results differed by analysis population; injectable treatment findings were preclinical.
Conclusion:
Hepatitis C elimination requires expanded prevention, diagnosis and curative treatment, supported by financing and integrated care. Vaccine development and single-injection treatment remain investigational.
Sources:
Based on findings from:
Hepatitis C elimination a 'political commitment challenge'
Matthew Solan. Idsa Reporter, 2026.
https://idsareporter.com/issues/2026/october-2026/hepatitis-c-elimination-a-political-commitment-challenge/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.